» Articles » PMID: 17484883

Whole-genome Analysis and HLA Genotyping of Enteropathy-type T-cell Lymphoma Reveals 2 Distinct Lymphoma Subtypes

Overview
Specialty Gastroenterology
Date 2007 May 9
PMID 17484883
Citations 63
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: Enteropathy-type T-cell lymphoma (ETL) is an aggressive extranodal T-cell non-Hodgkin lymphoma assumed to arise in the setting of celiac disease.

Methods: To precisely define the genetic alterations underlying the pathogenesis of ETL, 30 ETL samples were profiled for genetic copy number alterations using high-resolution whole-genome tiling path array comparative genomic hybridization. To investigate the potential association of genetic alterations in ETL with celiac disease, HLA-DQB1 genotyping was performed.

Results: By array comparative genomic hybridization, 13 novel recurrent minimal regions of chromosomal alteration were identified on multiple chromosome arms. ETL is characterized by frequent complex gains of 9q31.3-qter (70% of cases), or by an almost mutually exclusive 2.5-megabase loss of 16q12.1 (23% of cases). Two distinct groups of ETL could be delineated morphologically and genetically: type 1 ETL is characterized by nonmonomorphic cytomorphology, CD56 negativity, and chromosomal gains of 1q and 5q. Type 1 ETL also appears to be linked pathogenetically to celiac disease, sharing genetic alterations and HLA-DQB1 genotype patterns with (refractory) celiac disease. Type 2 ETL shows monomorphic small- to medium-sized tumor cell morphology, frequently shows CD56 expression, MYC oncogene locus gain, and rare gains of chromosomes 1q and 5q. In contrast to type 1 ETL, type 2 ETL shows a HLA-DQB1 genotype pattern more resembling that of the normal Caucasian population.

Conclusions: Contrary to current clinical classification, ETL comprises 2 morphologically, clinically, and genetically distinct lymphoma entities. In addition, type 2 ETL may not be associated with celiac disease.

Citing Articles

Prevalence of malignant neoplasms in celiac disease patients - a nationwide United States population-based study.

Haider M, Al Sbihi A, Reddy S, Green P World J Clin Oncol. 2024; 15(8):1048-1060.

PMID: 39193153 PMC: 11346075. DOI: 10.5306/wjco.v15.i8.1048.


Biology and genetics of extranodal mature T-cell and NKcell lymphomas and lymphoproliferative disorders.

Lewis N, Zhou T, Dogan A Haematologica. 2023; 108(12):3261-3277.

PMID: 38037802 PMC: 10690927. DOI: 10.3324/haematol.2023.282718.


Few and far between: clinical management of rare extranodal subtypes of mature T-cell and NK-cell lymphomas.

Stuver R, Epstein-Peterson Z, Horwitz S Haematologica. 2023; 108(12):3244-3260.

PMID: 38037801 PMC: 10690914. DOI: 10.3324/haematol.2023.282717.


Refractory celiac disease and its mimickers: a review on pathogenesis, clinical-pathological features and therapeutic challenges.

Scarmozzino F, Pizzi M, Pelizzaro F, Angerilli V, Dei Tos A, Piazza F Front Oncol. 2023; 13:1273305.

PMID: 38023263 PMC: 10662059. DOI: 10.3389/fonc.2023.1273305.


SOHO State of the Art Updates and Next Questions | Challenging Cases in Rare T-Cell Lymphomas.

Bhansali R, Barta S Clin Lymphoma Myeloma Leuk. 2023; 23(9):642-650.

PMID: 37302955 PMC: 10524462. DOI: 10.1016/j.clml.2023.05.012.